Trade QURE

uniQure B.V.

-

00:00:00

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson’s disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer’s disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read more...

QURE
Trading Specifications

Digits

3

Point

0.001

Spread

 
floating

Contract Size

1

Volume Min

1

Volume Max

10,000

Volume Step

1

Swap Long (Points)

 
-4.510

Swap Short (Points)

-2.610
Available on
MT5, TV, cTrader
Last update at April 12, 20:08 GMT+3
*Data Source: MT5 Server Prime Account Pricing

1D Change

3.299%

Why BlackBull Markets?

26k+

Tradable Assets

1:500

Leverage up to

Regulated

Multi-Regulated

24/7

Customer Support

$0

No Minimum Deposit

Margin Calculator

Calculation Results

Current Price

4.76

Required Margin

Converted Currency

Required Margin

Account Base Currency

Profit/Loss Calculator

PIP Value:

Stop loss in PIPs

Stop loss at:

Take profit in PIPs

Take profit at:

Join Now